These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

264 related articles for article (PubMed ID: 20570206)

  • 21. Intranigral administration of substance P receptor antagonist attenuated levodopa-induced dyskinesia in a rat model of Parkinson's disease.
    Yang X; Zhao H; Shi H; Wang X; Zhang S; Zhang Z; Zu J; Zhang W; Shen X; Cui G; Hua F
    Exp Neurol; 2015 Sep; 271():168-74. PubMed ID: 26001615
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Selegiline increases on time without exacerbation of dyskinesia in 6-hydroxydopamine-lesioned rats displaying l-Dopa-induced wearing-off and abnormal involuntary movements.
    Tsunekawa H; Takahata K; Okano M; Ishikawa T; Satoyoshi H; Nishimura T; Hoshino N; Muraoka S
    Behav Brain Res; 2018 Jul; 347():350-359. PubMed ID: 29526790
    [TBL] [Abstract][Full Text] [Related]  

  • 23. The protective effect of Mucuna pruriens seeds against snake venom poisoning.
    Tan NH; Fung SY; Sim SM; Marinello E; Guerranti R; Aguiyi JC
    J Ethnopharmacol; 2009 Jun; 123(2):356-8. PubMed ID: 19429384
    [TBL] [Abstract][Full Text] [Related]  

  • 24. The Role of Primary Motor Cortex (M1) Glutamate and GABA Signaling in l-DOPA-Induced Dyskinesia in Parkinsonian Rats.
    Lindenbach D; Conti MM; Ostock CY; George JA; Goldenberg AA; Melikhov-Sosin M; Nuss EE; Bishop C
    J Neurosci; 2016 Sep; 36(38):9873-87. PubMed ID: 27656025
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Evidence for a role for α6(∗) nAChRs in l-dopa-induced dyskinesias using Parkinsonian α6(∗) nAChR gain-of-function mice.
    Bordia T; McGregor M; McIntosh JM; Drenan RM; Quik M
    Neuroscience; 2015 Jun; 295():187-97. PubMed ID: 25813704
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Cabergoline and pramipexole fail to modify already established dyskinesias in an animal model of parkinsonism.
    Larramendy C; Taravini IR; Saborido MD; Ferrario JE; Murer MG; Gershanik OS
    Behav Brain Res; 2008 Dec; 194(1):44-51. PubMed ID: 18638507
    [TBL] [Abstract][Full Text] [Related]  

  • 27. The selective D(3) receptor antagonist, S33084, improves parkinsonian-like motor dysfunction but does not affect L-DOPA-induced dyskinesia in 6-hydroxydopamine hemi-lesioned rats.
    Mela F; Millan MJ; Brocco M; Morari M
    Neuropharmacology; 2010 Feb; 58(2):528-36. PubMed ID: 19733554
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Mucuna pruriens (L.) DC chemo sensitize human breast cancer cells via downregulation of prolactin-mediated JAK2/STAT5A signaling.
    Sinha S; Sharma S; Vora J; Shah H; Srivastava A; Shrivastava N
    J Ethnopharmacol; 2018 May; 217():23-35. PubMed ID: 29427634
    [TBL] [Abstract][Full Text] [Related]  

  • 29. The combination of oral L-DOPA/rimonabant for effective dyskinesia treatment and cytological preservation in a rat model of Parkinson's disease and L-DOPA-induced dyskinesia.
    Gutiérrez-Valdez AL; García-Ruiz R; Anaya-Martínez V; Torres-Esquivel C; Espinosa-Villanueva J; Reynoso-Erazo L; Tron-Alvarez R; Aley-Medina P; Sánchez-Betancourt J; Montiel-Flores E; Avila-Costa MR
    Behav Pharmacol; 2013 Dec; 24(8):640-52. PubMed ID: 24196024
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Striatal mRNA expression patterns underlying peak dose L-DOPA-induced dyskinesia in the 6-OHDA hemiparkinsonian rat.
    Smith LM; Parr-Brownlie LC; Duncan EJ; Black MA; Gemmell NJ; Dearden PK; Reynolds JN
    Neuroscience; 2016 Jun; 324():238-51. PubMed ID: 26968766
    [TBL] [Abstract][Full Text] [Related]  

  • 31. An improved model to investigate the efficacy of antidyskinetic agents in hemiparkinsonian rats.
    Spinnewyn B; Charnet C; Cornet S; Roubert V; Chabrier PE; Auguet M
    Fundam Clin Pharmacol; 2011 Oct; 25(5):608-18. PubMed ID: 21077938
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Low doses of sarizotan reduce dyskinesias and maintain antiparkinsonian efficacy of L-Dopa in parkinsonian monkeys.
    Grégoire L; Samadi P; Graham J; Bédard PJ; Bartoszyk GD; Di Paolo T
    Parkinsonism Relat Disord; 2009 Jul; 15(6):445-52. PubMed ID: 19196540
    [TBL] [Abstract][Full Text] [Related]  

  • 33. MK-801 inhibits L-DOPA-induced abnormal involuntary movements only at doses that worsen parkinsonism.
    Paquette MA; Anderson AM; Lewis JR; Meshul CK; Johnson SW; Paul Berger S
    Neuropharmacology; 2010 Jun; 58(7):1002-8. PubMed ID: 20079362
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Genetic silencing of striatal CaV1.3 prevents and ameliorates levodopa dyskinesia.
    Steece-Collier K; Stancati JA; Collier NJ; Sandoval IM; Mercado NM; Sortwell CE; Collier TJ; Manfredsson FP
    Mov Disord; 2019 May; 34(5):697-707. PubMed ID: 31002755
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Development and validation of an LC-MS/MS method for simultaneous quantification of levodopa and MD01 in rat plasma and its application to a pharmacokinetic study of mucuna pruriens extract.
    Yang G; Zhang F; Deng L; Chen C; Cheng Z; Huang J; Liu J; Jiang H
    Biomed Chromatogr; 2016 Sep; 30(9):1506-14. PubMed ID: 26928470
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Effect of the metabotropic glutamate antagonist MPEP on striatal expression of the Homer family proteins in levodopa-treated hemiparkinsonian rats.
    Jiménez A; Bonastre M; Aguilar E; Marin C
    Psychopharmacology (Berl); 2009 Oct; 206(2):233-42. PubMed ID: 19636538
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Mucuna pruriens (L.) DC. seed extract inhibits lipopolysaccharide-induced inflammatory responses in BV2 microglial cells.
    Rachsee A; Chiranthanut N; Kunnaja P; Sireeratawong S; Khonsung P; Chansakaow S; Panthong A
    J Ethnopharmacol; 2021 Mar; 267():113518. PubMed ID: 33122120
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Antiparkinson drug--Mucuna pruriens shows antioxidant and metal chelating activity.
    Dhanasekaran M; Tharakan B; Manyam BV
    Phytother Res; 2008 Jan; 22(1):6-11. PubMed ID: 18064727
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Inhaling xenon ameliorates l-dopa-induced dyskinesia in experimental parkinsonism.
    Baufreton J; Milekovic T; Li Q; McGuire S; Moraud EM; Porras G; Sun S; Ko WKD; Chazalon M; Morin S; Normand E; Farjot G; Milet A; Pype J; Pioli E; Courtine G; Bessière B; Bezard E
    Mov Disord; 2018 Oct; 33(10):1632-1642. PubMed ID: 29756234
    [TBL] [Abstract][Full Text] [Related]  

  • 40. 5-Hydroxy-tryptophan for the treatment of L-DOPA-induced dyskinesia in the rat Parkinson's disease model.
    Tronci E; Lisci C; Stancampiano R; Fidalgo C; Collu M; Devoto P; Carta M
    Neurobiol Dis; 2013 Dec; 60():108-14. PubMed ID: 24004632
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 14.